HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearchCompany Lookup
The Week

Takeda's $4B TYK2 drug tops Bristol Myers' Sotyktu in head-to-head test

The results support Takeda's long-held belief in zasocitinib's superiority and could help it gain a commercial advantage over Bristol's therapy.

By BioPharma Dive · Jun 11, 2026 · via BioPharma Dive
Takeda's $4B TYK2 drug tops Bristol Myers' Sotyktu in head-to-head test

Image: BioPharma Dive

This is an aggregated industry headline. Read the full story at BioPharma Dive →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
CG Life embraces next-gen era in merger with AI-native agency The Considered+AI
The Considered+AI is an AI-native agency that's been rooted in generative AI tools since its start in 2021.…
Jul 29, 2026
The WeekFierceBiotech ↗
Eli Lilly tops new biopharma ranking on launch success, development speed
Flush with GLP-1 cash and pipeline success, Eli Lilly rose from 16th to first over five years in Norstella's i…
Jul 29, 2026
Freenome gets FDA signoff, Abbott takes the U.S. commercialization role
The WeekBriefing
Freenome gets FDA signoff, Abbott takes the U.S. commercialization role
Freenome’s blood-based colorectal cancer test won FDA approval, and Abbott will exclusively market it in the U…
Jul 29, 2026